Effect of ivabradine versus placebo on cardiac function, exercise capacity, and neuroendocrine activation in patients with Chronic Heart Failure with Preserved left ventricular Ejection Fraction An 8-month, randomised double-blind, placebo controlled, international, multicentre study.
Latest Information Update: 11 Jun 2019
Price :
$35 *
At a glance
- Drugs Ivabradine (Primary)
- Indications Chronic heart failure
- Focus Proof of concept; Therapeutic Use
- Acronyms EDIFY
- Sponsors IRIS; Servier
- 30 Apr 2017 Primary endpoint (Echo-Doppler E/e ratio) has not been met, according to the results published in the European Journal of Heart Failure
- 30 Apr 2017 Primary endpoint (B-type natriuretic peptide levels (NT-proBNP)) has not been met, according to the results published in the European Journal of Heart Failure
- 30 Apr 2017 Primary endpoint (Six-minute walking distance) has not been met, according the results published in the European Journal of Heart Failure